Noninvasive Assessment of Fibrosis Regression after Direct-acting Antiviral Treatment in Hepatitis C Virus Patients

• Published in: The Israel Medical Association journal Vol. 23; no. 12; pp. 794 - 800
• Main Authors: Davidov, Yana, Kleinbaum, Yeruham, Inbar, Yael, Cohen-Ezra, Oranit, Veitsman, Ella, Weiss, Peretz, Likhter, Mariya, Berdichevski, Tania, Katsherginsky, Sima, Hassid, Avishag, Tsaraf, Keren, Silverberg, Dana, Ben Ari, Ziv
• Format: Journal Article
• Language: English
• Published: Israel 01-12-2021
• Subjects: Adult; Aged; Aged, 80 and over; Antiviral Agents - administration & dosage; Elasticity Imaging Techniques; Female; Follow-Up Studies; Hepacivirus - drug effects; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - drug therapy; Humans; Liver Cirrhosis - drug therapy; Liver Cirrhosis - virology; Male; Middle Aged; Splenomegaly - epidemiology; Sustained Virologic Response; Time Factors; Treatment Outcome
• ISSN: 1565-1088

New direct acting antiviral agent (DAA) therapies are associated with a high sustained virological response rate (SVR) in hepatitis C virus (HCV) patients. The understanding of the impact of SVR on fibrosis stage is limited.
To determine the effect of treatment with the DAAs on long-term liver fibrosis stages, as determined by shear-wave elastography (SWE) or FibroTest.
Fibrosis stage was determined at baseline and at 6-month intervals after end of treatment (EOT), using two-dimensional SWE or FibroTest©; APRI and FIB-4 scores.
The study comprised 133 SVR12 patients. After a median follow-up of 15 months (range 6-33), liver fibrosis stage decreased by at least 1 stage in 75/133 patients (56%). Cirrhosis reversal was observed in 24/82 (29%). Repeated median liver stiffness SWE values in cirrhotic patients were 15.1 kPa at baseline (range 10.5-100), 13.4 kPa (range 5.5-51) at 6 months, and 11.4 kPa (range 6.1-35.8) at 12 months after EOT, P = 0.01. During the second year after EOT, no statistically significant differences in liver fibrosis stage in 12, 18, and 24 months were found. Splenomegaly was the only significant negative predictor of liver fibrosis regression during all time points of repetitive noninvasive assessment.
Following successful DAA treatment, the majority of our HCV patients with advanced fibrosis demonstrated significant improvement, as assessed by non-invasive methods. Advanced fibrosis stage was a negative predictor of fibrosis regression. Longer follow-up periods are required to further establish the impact of DAAs treatment in HCV patients with advanced fibrosis.